Evgen Pharma plc (EVG) Ordinary 0.25p
Evgen Pharma plc Ordinary 0.25p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Client deadline
- Add to watchlist
- Create an alert
- This stock can be held in a
Evgen Pharma plc Ordinary 0.25p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Client deadline
Evgen Pharma plc Ordinary 0.25p
- Type:
- Miscellaneous
- Shareholder action required:
- Yes
- Status:
- Client deadline
Share news, reports & tips
-
Evgen upbeat on start of glioblastoma research project
26 October 2023 11:08
(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a...
-
Evgen Pharma doses first volunteers in SFX-01 trial
16 November 2022 14:05
(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it...
-
Evgen starts recruiting volunteers for trial of lead asset
12 October 2022 12:23
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to...
-
Evgen agrees fresh licensing deal with Spanish institutions
18 January 2022 11:48
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and...
-
Evgen pleased with preclinical data on SFX-01
13 July 2021 15:36
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on...
-
Evgen 'surprised and disappointed' by findings in SFX-01 trial
9 July 2021 10:33
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR'...
-
Evgen upbeat on new data on potential breast cancer treatment
14 June 2021 11:00
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC)...
Company announcements Announcements
-
Retail Offer
19 March 2024 17:03
Evgen Pharma
-
Acquisition, Fundraising and Change of Name
19 March 2024 17:00
Evgen Pharma
-
Notice of Dispute lodged with Stalicla SA
9 February 2024 11:01
Evgen Pharma
-
Holding(s) in Company
29 December 2023 11:29
Evgen Pharma
-
Directorate Changes
22 December 2023 07:00
Evgen Pharma
-
Half-year Report
31 October 2023 07:00
Evgen Pharma
-
Directorate Changes
5 September 2023 07:00
Evgen Pharma
-
Final Report from Phase 1b PK/PD study
15 August 2023 07:00
Evgen Pharma
-
Rule 17 Disclosure
3 August 2023 12:38
Evgen Pharma
-
Return of rights to Sulforadex from Juvenescence
2 August 2023 07:00
Evgen Pharma
-
Result of AGM
21 July 2023 12:02
Evgen Pharma
-
Notice of AGM & Posting of Annual Report
20 June 2023 13:59
Evgen Pharma
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.